The BRUIN CLL-321 is the first randomized phase III comparing pirtobrutinib with idelalisib plus rituximab or bendamustine plus rituximab in patients with R/R CLL previously treated with a BTK inhibitor. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.